Treatment of renal cell carcinoma with systemic administration of intermediate doses of recombinant human interleukin-2 alone. Recombinant Human Interleukin-2 (S-6820) Research Group on Renal Cell Carcinoma
-
- Aso
- Creator
Journal
-
- Prog. Clin. Biol. Res.
-
Prog. Clin. Biol. Res. 303 681-, 1989